ofatumumab News
Most Popular ofatumumab Story
GSK, Genmab report strong ofatumumab data
So far, it looks like GlaxoSmithKline's $2.1 billion deal for HuMax-CD20 was money well spent. Inerim data from a Phase... Read more...
Latest Headlines
- August 1, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


